• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

OBJECTIVE: Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology. RESEARCH DESIGN AND METHODS: We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, inflammatory, and metabolic genes. We tested 32,088 SNPs for an association with edema among Europeans who received rosiglitazone (n = 965). RESULTS: One SNP, rs6123045, in NFATC2 was significantly associated with edema (odds ratio 1.89 [95% CI 1.47-2.42]; P = 5.32 × 10(-7), corrected P = 0.017). Homozygous individuals had the highest edema rate (hazard ratio 2.89, P = 4.22 × 10(-4)) when compared with individuals homozygous for the protective allele, with heterozygous individuals having an intermediate risk. The interaction between the SNP and rosiglitazone for edema was significant (P = 7.68 × 10(-3)). Six SNPs in NFATC2 were significant in both Europeans and Latin Americans (P < 0.05). CONCLUSIONS: Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone.

Pubmed ID: 20628086


  • Bailey SD
  • Xie C
  • Do R
  • Montpetit A
  • Diaz R
  • Mohan V
  • Keavney B
  • Yusuf S
  • Gerstein HC
  • Engert JC
  • Anand S
  • DREAM investigators


Diabetes care

Publication Data

October 29, 2010

Associated Grants

  • Agency: British Heart Foundation, Id: RG/08/012/25941
  • Agency: Canadian Institutes of Health Research, Id:

Mesh Terms

  • Diabetes Mellitus, Type 2
  • Edema
  • Female
  • Humans
  • Hypoglycemic Agents
  • Male
  • NFATC Transcription Factors
  • Polymorphism, Single Nucleotide
  • Ramipril
  • Thiazolidinediones